Plasma adrenomedullin concentrations in patients with adrenal pheochromocytoma

What Was Tested

This randomized controlled trial paper looks at Adrenomedullin.

1) to investigate whether plasma adrenomedullin levels were changed in 10 patients with pheochromocytoma when compared to 21 healthy subjects and 16 patients with essential hypertension; 2) to determine whether or not adrenomedullin has a counter-regulatory role in catecholamine excess in pheochromocytoma or is responsible for hemodynamic modifications before and after tumour resection; 3) to determine tissue distribution of iradrenomedullin in the pheochromocytoma.

Why It Was Studied

The hypotensive peptide adrenomedullin was first isolated in extracts of human pheochromocytoma.

There is, however, no information available on the behaviour of circulating adrenomedullin or on the correlation with catecholamines in patients with pheochromocytoma.

Who Took Part

The abstract describes 10 patients taking part.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

Plasma adrenomedullin and catecholamine levels were measured in all patients with pheochromocytoma before and four weeks after tumour removal.

In the four patients undergoing resection of tumours, plasma levels of adrenomedullin were measured at different time-points during surgery.

How the Study Was Run

In design terms this was a randomized study.

Because people in this Adrenomedullin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

What Was Measured

PubMed files the paper under topics including Adrenal Gland Neoplasms, Adrenalectomy, Adrenomedullin, Catecholamines, Hemodynamics, Hypertension and Immunohistochemistry.

What This Means in Plain Language

The paper is a randomized study of Adrenomedullin in 10 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2001 (Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme), a journal based in Germany.

More context: the Adrenomedullin compound page, all human trials.